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(48 male/14 female) with moderate IPF (FVC 64 ± 17% pred. 
and D LCO 40 ± 10% pred.) were treated with nintedanib. 77% 
of patients switched from pirfenidone (mean treatment du-
ration 14 ± 2 months) mostly due to disease progression 
(mean decline in FVC 7.4 ± 3% pred. in the 6 months prior to 
nintedanib intake). Initiation of nintedanib treatment oc-
curred 69 ± 29 months after IPF diagnosis, and mean treat-
ment duration was 8 ± 4 months. Most patients (63%) stabi-
lized 6 months after treatment start (mean FVC decline 3 ± 1 
vs. –17 ± 2% in patients with disease progression; p < 0.01). 
The most common adverse events were diarrhea (63%) and 
weight loss (50%). Dose reduction occurred in 34% of cases 
and treatment discontinuation in 10%.  Conclusion: Ninte-
danib treatment was generally well tolerated and was asso-
ciated with FVC stabilization in the majority of IPF patients in 
this CUP setting where most patients were not treatment 
naïve. Our data are in agreement with the previously pub-
lished data.  © 2016 The Author(s)
Published by S. Karger AG, Basel 
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 Abstract 
 Background: Nintedanib is approved for the treatment of 
idiopathic pulmonary fibrosis (IPF) and has been shown to 
slow disease progression by reducing annual lung function 
decline.  Objective: To evaluate the results of a large cohort 
of IPF patients treated with nintedanib within a compassion-
ate use program (CUP) in Germany (9 centers).  Methods: Pa-
tients ( ≥ 40 years) were required to have a confirmed diag-
nosis of IPF, a forced vital capacity (FVC)  ≥ 50% predicted 
(pred.) and a carbon monoxide diffusing capacity (D LCO ) 30–
79% pred. and not to be eligible for pirfenidone treatment. 
Clinical data, pulmonary function tests and adverse events 
were recorded up to July 2015.  Results: Sixty-two patients 
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 Idiopathic pulmonary fibrosis (IPF) is a chronic, pro-
gressive and finally lethal lung disease with a frequency of 
2.8–9.3 per 100,000 per year in Europe and North Amer-
ica  [1] . The deterioration of respiratory function over 
time and IPF-related complications heavily affect the 
quality of life of IPF patients  [2] . There are two approved 
antifibrotic drugs for IPF, which cannot stop the disease 
course, but can considerably reduce the decline of lung 
function: nintedanib and pirfenidone  [3, 4] .
 Nintedanib has been investigated in three internation-
al phase II (TOMORROW) and phase III clinical trials 
(INPULSIS ® -1 and INPULSIS ® -2) including almost 
1,500 patients with IPF  [5, 6] . In both INPULSIS ® trials, 
the primary outcome was achieved, with a reduction in 
the annual rate of forced vital capacity (FVC) decline of 
approximately 50% in the nintedanib group compared to 
placebo  [6] . The most frequently reported adverse event 
(AE) in these trials was diarrhea, which was reported in 
62% of patients treated with nintedanib compared to 18% 
in the placebo group. Diarrhea events were mild to mod-
erate in intensity in the vast majority of patients and led 
to premature treatment discontinuation in fewer than 5% 
of nintedanib-treated patients  [6] .
 The twin phase III INPULSIS ® trials and the phase II 
TOMORROW study were all followed by open-label ex-
tension trials to provide ongoing treatment options to pa-
tients who completed the studies and to assess long-term 
safety and tolerability of nintedanib treatment  [7–9] . 
More than 90% of eligible patients (n = 734/807) chose to 
continue to receive open-label nintedanib in the ongoing 
INPULSIS ® -ON extension trial, following completion of 
the INPULSIS ® trials  [7, 8] . Interim results from this 
study have recently been reported and confirmed the 
long-term safety and tolerability profile of nintedanib in 
IPF  [7, 8] . Recently, a phase II study assessed the safety, 
tolerability, and pharmacokinetic profile of nintedanib 
when given alone or in addition to pirfenidone treatment 
in Japanese patients  [10] . In addition, 2 open-label trials 
investigating the long-term safety and tolerability of the 
combination nintedanib plus pirfenidone are ongoing 
(www.clinicaltrials.gov identifier No. NCT01417156 and 
NCT02598193).
 Whereas data and subgroup analyses from patients 
treated with nintedanib in clinical trials have been report-
ed, the use of nintedanib in real-life settings has not been 
reported in detail. Compassionate use programs (CUP) 
are intended to facilitate the availability of new treatment 
options under development to patients before they are 
available commercially  [11] and allow for data to be col-
lected on use of products under conditions of clinical 
practice. The nintedanib CUP was offered by Boehringer 
Ingelheim GmbH (Ingelheim, Germany) in May 2014 to 
enable early access to nintedanib for patients with IPF af-
ter publication of the results from the pivotal INPULSIS 
trials in May 2014. Here, we report the efficacy and safety 
of a large cohort of IPF patients who received nintedanib 
within a CUP in Germany.
 Patients and Methods 
 The Compassionate Use Program 
 To be eligible for treatment with nintedanib in the CUP, pa-
tients were required to be over 40 years of age, with a confirmed 
diagnosis of IPF in accordance with international guidelines  [12] . 
Carbon monoxide diffusing capacity (D LCO ) had to be 30–79% 
predicted (pred.) based on international standards, and FVC 
 ≥ 50% pred. based on institutional standards  [13, 14] . Patients were 
required to be judged as not eligible for treatment with pirfeni-
done, based on disease severity and/or intolerability, by the treat-
ing clinician, and the decision to prescribe nintedanib was based 
on clinician’s judgement. Key exclusion criteria included alanine 
aminotransferase (ALT)/aspartate aminotransferase (AST) or bil-
irubin levels greater than 1.5 times the upper limit of normal 
(ULN); risk of bleeding or thrombosis; planned major surgery 
within the next 3 months, including lung transplantation, major 
abdominal, or major intestinal surgery; myocardial infarction 
within the last 6 months, or unstable angina within the last month. 
All patients were assessed for study eligibility by central review.
 All patients provided written informed consent, and the re-
quired regulatory authorities (Federal Institute for Drugs and Med-
ical Devices and regional authorities) were informed; as this was a 
CUP, ethics committee approval was not required. The CUP was 
conducted in accordance with the Ordinance on Medicinal Prod-
ucts for Compassionate Use  [15] . It was initiated in May 2014 and 
stopped upon market availability of nintedanib for the treatment of 
IPF in Germany (February 2015) as applicable by German law.
 Drug Intake 
 Nintedanib was given as continuous oral treatment at a starting 
dose of 150 mg twice daily. Dose interruption or reduction of the 
150 mg twice daily to 100 mg twice daily was allowed for the man-
agement of AEs. The dose could be retitrated to 150 mg twice dai-
ly upon resolution of the AE. Dose reductions below 100 mg twice 
daily were not permitted. Hepatic transaminases (AST and ALT) 
monitoring was recommended on a monthly basis during the first 
3 months after treatment initiation and at least every 3 months 
thereafter. Recommendations for the management of diarrhea and 
elevated levels of liver enzymes were provided.
 Patients were required to permanently discontinue nintedanib 
if they experienced significant liver function impairment or recur-
rent grade 3/4 diarrhea. Concomitant medications to allow ade-
quate care of the patient were permitted as clinically necessary; 
concomitant therapies that were not permitted during the study 
are given in online supplemental table S1 (for all online suppl. ma-
terial, see www.karger.com/doi/10.1159/000448288).
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 Data Collection 
 Participating clinicians were asked to retrospectively provide 
data for each patient treated in the CUP including: demographics 
and baseline characteristics (gender, age, comorbidities, disease 
history and prior and concomitant medications); pulmonary func-
tion tests at 6 months prior to initiation of therapy, at nintedanib 
treatment baseline and 6 months after start of treatment; FVC, 
maximum vital capacity and D LCO and radiological assessment. 
Patients were followed-up for as long as possible prior to the end 
of the CUP; for patients treated with nintedanib for longer than
6 months, additional follow-up visits were conducted as appropri-
ate. Blood gas analysis results were also collected as well as infor-
mation on long-term oxygen requirement at baseline and follow-
up. Patient self-reported symptoms were also collected at each fol-
low-up. Information on AEs, including nonserious, serious, AEs 
of special interest, AEs leading to treatment discontinuation or 
dose reduction/interruption of nintedanib were required to be 
centrally reported to Boehringer Ingelheim.
 Clinical Definitions 
 Patients were required to have a follow-up and/or intake of 
nintedanib  ≥ 3 months to be included in the efficacy analysis. Dis-
ease progression was defined as an absolute decline in FVC pred. 
 ≥ 5% from baseline over 6 months. Patients with a decline in FVC 
pred. <5% from baseline were classified as having stable disease 
provided they had no worsening of symptoms or radiological find-
ings. Other outcomes included change of self-reported respiratory 
symptoms and IPF-related radiological findings over time. These 
outcomes were considered exploratory as there was no standard-
ization of data collection (symptom reporting was ad hoc, and cri-
teria for radiological evaluation were not defined).
 Statistics 
 The Kolmogorov-Smirnov test was used to test variable distri-
bution. Continuous normally distributed variables are expressed 
as mean ± standard error of the mean, while non-normally distrib-
uted data are expressed by median and interquartile range. Paired 
t test was used to compare lung function tests over time. Differ-
ences in proportions of subjects showing a change of %FVC before 
and after treatment were analyzed using the McNemar χ 2 test. A p 
value <0.05 was considered significant for all analyses. All analyses 
were conducted using IBM © SPSS © statistic software (version 21).
 Results 
 Patients 
 A total of 83 patients with IPF received treatment with 
nintedanib as part of the CUP. Here, we report data on 62 
patients treated at 9 centers across Germany who began 
treatment between May 2014 and January 2015; data on 
the remaining 21 patients were not provided by the treat-
ing centers. All data from treatment initiation to the cut-
off date of 31 July 2015 were collected.
 Patient demographics and baseline clinical character-
istics are shown in  table 1 . The majority of patients were 
male (77%) and ex-smokers (61%) with moderate func-









Time since IPF diagnosis, months 69±29
Medical co-morbidity
Arterial hypertension 19 (31)
Type 2 diabetes 9 (14.5)
Coronary heart disease 8 (13)
Gastroesophageal reflux disease 7 (11)
Obstructive sleep apnea syndrome 4 (6)
Other 3 (5)
Prior treatments for IPF




N-acetylcysteine and/or steroids 11 (17)
N-acetylcysteine, alone or in combination 9 (14.5)
Immunosuppressive, alone or in
combination 8 (13)
None 9 (14.5)
Duration of pirfenidone treatment, months 13.5±1.6
Reasons for discontinuation of previous
pirfenidone treatment (n = 48; 100%)
Tolerability 27 (56)
Disease progression 21 (44)
Concomitant medications at baseline
ACE inhibitors/ARB/diuretics 19 (31)
Proton pump inhibitors 16 (26)








FVC, % predicted 64±17
DLCO, % predicted 40±10
PaO2, mm Hg 67±0
Long-term oxygen treatment at start 5 (8)
 Data are presented as n (%) or mean ± SEM. ACE = Angiotensin-
converting enzyme; ARB = angiotensin receptor blockers.
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tional impairment at the start of treatment (FVC of 64 ± 
17%, D LCO 40 ± 10% pred.). Five patients were on long-
term oxygen treatment.
 Patients were 71 years old on average, and the diagno-
sis of IPF was made 69 ± 29 months prior to the start of 
nintedanib treatment. The most frequent observed co-
morbidity was arterial hypertension (31%) followed by 
type 2 diabetes (15%).
 Before starting treatment with nintedanib, the major-
ity of patients (n = 48, 77%) had been receiving treatment 
with pirfenidone, either alone or in combination with 
other IPF treatments, for a mean duration of 14 ± 2 
months ( table 1 ). Fourteen patients (23%) were not re-
ceiving pirfenidone at the time of starting nintedanib 
treatment due to: comorbidity (n = 1); patient reluctance 
to take pirfenidone due to concerns about the general tol-
erability profile (n = 2) or possible phototoxic effects (n = 
5); tolerability issues with previous pirfenidone treatment 
(n = 3); failure of previous pirfenidone (n = 1), or un-
known reasons (n = 2).
 Duration of Treatment and Compliance 
 The follow-up duration in the CUP ranged from 2 to 
14 months, with a mean follow-up of 9 ± 2.4 months. Ex-
posure to nintedanib ranged from 0.5 to 14 months with 
a mean of 8 ± 4 months. As of the cutoff date (31 July 
2015), 7 patients (11%) had permanently discontinued 
treatment with nintedanib, and a further 18 patients 
(29%) had required a temporary treatment interruption. 
The reasons for permanent and temporary treatment dis-
continuation are shown in  table 2 . The average time to 
treatment discontinuation was 106 (range 3–327) days af-
ter treatment initiation. The median (range) duration of 
temporary discontinuation was 17 (1–91) days.
 Disease Outcome under Nintedanib Treatment 
 Decline in FVC 
 Of the 62 patients treated within the CUP, FVC data 
were available for 48 patients at 6 months and for 36 at 
the last follow-up visit; data on 14 patients were excluded 
from the analysis due to missing data at follow-up (n = 4) 
or too short (<3 months) nintedanib intake (n = 10).
 In the 6 months prior to initiating therapy with nint-
edanib, the mean change in FVC had been –7.4 ± 3% 
pred. The change in FVC 6 months prior to nintedanib 
initiation was significantly lower in patients who had 
been receiving pirfenidone (n = 42) than in those who did 
not receive antifibrotic therapy (n = 13) (–5.2 ± 3.9 vs. 
–17.6 ± 3.7% pred.; p = 0.027).
 At 6 months following the initiation of nintedanib, 30 
patients (63%) were classified as having stable disease as 
defined by a decline in FVC of <5% from baseline; the re-
maining 18 patients (37%) were classified as experiencing 
disease progression.  Figure 1 shows the course of pulmo-
nary function measured using FVC before and after ini-
tiation of treatment with nintedanib in patients based on 
whether or not they suffered from stable or progressive 
disease at 6 months. The mean change in FVC at 6 months 
was 3.1 ± 1.2% from baseline in stable patients compared 
to –17 ± 2% in patients with disease progression (p < 
0.01). A similar pattern of pulmonary function was also 
observed at the last follow-up visit (average 8 ± 0.5 months 
after first intake of nintedanib) at which time 64% of pa-
tients were classified as having stable disease and 36% of 
patients were classified as having disease progression; the 
mean change in FVC was 1.6 ± 1.2 versus –13.3 ± 1.8%, 
respectively (p < 0.01).
 Table 2. Reasons for treatment discontinuation/interruption and 
AEs reported during the observation period (n = 62)
Permanent discontinuation of treatment 7 (11)
Death 3 (5)
Adverse events 2 (3)
Disease progression 2 (3)
Temporary discontinuation 18 (29)
Adverse events
Diarrhea 10 (16)
Liver enzyme elevations 2 (3)
Progression 6 (10)
Adverse events requiring dose reduction 21 (34)
Diarrhea 19 (31)
Liver enzyme elevations 2 (3)
Any adverse events 47 (75.8)





AST/ALT increase >3× ULN 5 (8.1)
Weight loss 31 (50.0)
Mean weight loss, kg 3.2±1
Fatigue 24 (38.7)
Cough worsening 9 (14.5)
Skin rash 6 (9.7)
Dizziness 4 (6.5)
Headache 3 (4.8)
Ischemic stroke 2 (3)
Other <3 (<4.8)
Data are presented as n (%) or mean ± SEM. No bleeding events 
were reported.
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 In the patients who had progressed while on pirfeni-
done (n = 21), the change in FVC was –17.3 ± 6% pred. 
in the 6 months prior to entering the CUP. Among those 
patients, 13 (62%) stabilized (FVC change –18.2 ± 6% 
pred. before treatment compared to 2 ± 1.8% pred. after 
treatment) and 8 (38%) continued to progress (FVC 
change –15.7 ± 4% pred. before treatment compared to 
–18 ± 11% pred. after treatment) ( fig. 2 ). Among the pa-
tients who were stable under pirfenidone but did not tol-











































 Fig. 1. FVC before and after initiation of treatment with nintedanib in patients with stable disease (n = 30;  a ) and 
disease progression (n = 18;  b ) with nintedanib. 
 Fig. 2. FVC before and after initiation of treatment with nintedanib in patients with stable disease (n = 13;  a ) and 
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pred. before treatment compared to 3 ± 2% pred. after 
treatment) and 5 (30%) had progression (FVC change 
–18 ± 20% pred. before treatment compared to –21 ± 2% 
pred. after treatment) under nintedanib.
 Figure 3 shows the categorical change in FVC 6 months 
before and after initiation of nintedanib therapy. After 6 
months of nintedanib therapy, more patients had an FVC 
decline <5% than in the 6 months prior to nintedanib (60 
vs. 30%). There was no association between the decline in 
FVC in the 6 months prior to nintedanib treatment and 
outcome at 6 months (p = 0.718) or at the last follow up 
visit (p = 0.417). The decline in FVC did not differ in pa-
tients receiving nintedanib plus N-acetylcysteine from 
those receiving nintedanib alone (data not shown).
 Decline in D LCO 
 D LCO data were available for 36 patients at 6 months 
and 19 patients at the last follow-up visit. The outcome 
of patients is summarized in  table 3 . At 6 months follow-
ing initiation of nintedanib, 18 patients (50%) were clas-
sified as having stable disease as defined by a decline in 
D LCO of <15% from baseline. A similar trend for less de-
cline in mean D LCO in patients with stable disease com-
pared to those with disease progression was seen, but no 
significance was reached due to the low number of mea-







6 months prior to
nintedanib therapy









FVC <5% FVC  >10%
 Fig. 3. Categorical decline in FVC 6 months 
before and after nintedanib treatment and 
at last follow-up visit. p = 0.008, variation 
in the frequency of response categories 
over all time points (χ 2 test). 






Stable disease 30 (62.5) 18 (50.0) 36 (85.7) 22 (57.9)
Progression 18 (37.5) 18 (50.0) 6 (14.3) 16 (42.1)
Missing data 14 26 20 24
Last follow-up visit
Stable disease 23 (63.9) 15 (78.9) 26 (74.3) 17 (65.4)
Progression 13 (36.0) 4 (21.1) 9 (25.7) 9 (34.6)
Missing data 26 43 27 36
Data are presented as n (%). Stable disease was defined as: FVC decline <5%; DLCO decline <15%, and  based on investigator 
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 Additional Outcomes 
 Radiological outcomes and results from patient-re-
ported symptomatic assessment are shown in  table 3 . Sta-
ble disease, based on radiological assessment by the inves-
tigator, was reported in 86% (n = 36/42) of patients at 6 
months after treatment and 74% (n = 26/35) of patients 
at the last visit.
 At initiation of nintedanib treatment, the majority of 
patients (n = 47/56; 84%) had reported a worsening of 
dyspnea and/or cough within the previous 6 months. Fol-
lowing 6 months of nintedanib treatment, 61% (n = 
22/38) of patients considered these symptoms to be
stable.
 During the observation period, 7 patients experienced 
acute exacerbations, all of which were classified as ‘sus-
pected acute’ exacerbation on the basis of proposed crite-
ria  [16] . Seven patients died during the observation pe-
riod; 3 deaths were due to acute exacerbation of IPF, 3 due 
to pneumonia and 1 had an unknown cause.
 Tolerability of Nintedanib Treatment 
 Side Effects 
 AEs reported over the observation period are shown in 
 table 2 . At least one AE was reported by 76% of patients, 
while 24% did not report any AE. No severe AEs were re-
ported.
 Gastrointestinal AEs were reported by 67% of patients, 
the most common of which was diarrhea (63%), followed 
by anorexia (39%) and nausea (26%). As per guidelines 
provided for the management of AEs, patients experienc-
ing diarrhea were prescribed loperamide. Twenty-six pa-
tients (42%) were prescribed loperamide 2 mg on a regu-
lar basis for the management of diarrhea. The average 
loperamide use was 5 tablets (each of 2 mg) per week 
(range 1–20). Weight loss was reported in half of all pa-
tients, with a mean decrease of 3.2 ± 1 (range 0–21) kg 
over 6 months in those who experienced weight loss.
 Elevations in AST/ALT greater than 3 times the ULN 
were reported in 5 patients (8%). Following temporary 
treatment discontinuation, these elevations generally 
returned to within-normal limits, and nintedanib treat-
ment was restarted at a reduced dose without further 
AST/ALT elevations. Two patients suffered an ischemic 
stroke during the study period; no other cardiovascular 
events were reported. No bleeding events were re-
ported.
 No significant difference in the incidence of side ef-
fects or drug discontinuation was seen in patients who 
received N-acetylcysteine plus nintedanib versus ninte-
danib alone (data not shown).
 Dose Reduction 
 In total, 21 patients (34%) required a dose reduction 
due to AEs; AEs leading to dose reduction are shown in 
 table 2 . Of the 21 patients that required dose reduction, 
12 had a dose reduction after temporary interruption of 
treatment and remained at the reduced dose until the end 
of follow-up; 7 patients had a dose reduction and then 
permanently discontinued treatment, and 2 patients had 
a temporary dose reduction followed by a rechallenge to 
the full dose.
 Discussion 
 To our knowledge, this is the first report on a prospec-
tive cohort of patients with IPF treated with nintedanib 
in the real-life setting. Patients treated within the CUP 
typically had more advanced IPF than patients treated in 
clinical trials, and they were older. Nintedanib treatment 
was associated with disease stabilization within 6 months, 
as measured by FVC, in the majority (63%) of IPF pa-
tients; disease stabilization also occurred in two thirds of 
patients who previously had progression under pirfeni-
done (n = 13/21). Nintedanib was generally well tolerated 
with a manageable AE profile.
 Clinical trials are an essential part of drug develop-
ment, yet the strict inclusion and exclusion criteria em-
ployed often result in a patient population that differs 
from that seen in clinical practice. While there were sim-
ilarities in the eligibility criteria between the CUP and the 
INPULSIS clinical trials, there were also important differ-
ences. In our cohort, for example, treatment was started 
on average 5.8 years after IPF diagnosis in comparison to 
1.6 years in the INPULSIS trials  [6] . Respiratory function 
at baseline also differed, with mean FVC markedly lower 
than in INPULSIS (64 vs. 80% pred., respectively) and 
mean D LCO about 7% lower than in INPULSIS (40 vs. 
47% pred., respectively). This clinical setting is also re-
lated to the fact that the majority of CUP patients had 
received a number of previous treatments for IPF, the ma-
jority of them had pirfenidone for longer than 1 year, and 
had a significant decline in the 6 months prior to the start 
of nintedanib. Patients in the CUP were also permitted to 
receive N-acetylcysteine treatment, which was an exclu-
sion criterion in INPULSIS. With regard to comorbidi-
ties, another important difference is that cardiac disease 
was present in 13% of patients in the CUP, consistent with 
previous data in this patient population  [17] ; the INPUL-
SIS trials specifically excluded patients with myocardial 
infarction within 6 months or unstable angina within 1 
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month of randomization. A further comparison between 
the CUP and INPULSIS cohorts with regard to comor-
bidities is not possible since the details of comorbidities 
were not given in the INPULSIS publication.
 Although the CUP cohort consisted of patients with 
moderate/advanced IPF in the majority of patients (63%), 
FVC stabilized under treatment with nintedanib within 6 
months. The reduction in the decline in FVC reported in 
the CUP cohort was  ∼ 58% (reduction from 7.4% before 
treatment to 3% after 6 months) in patients who stabi-
lized; a  ∼ 50% reduction at 12 months was observed in the 
INPULSIS trials.
 Patient self-reporting of symptom improvement and 
radiological findings were consistent with FVC findings. 
We did not observe any influence of concomitant medi-
cation, especially N-acetylcysteine, or comorbidities on 
the decline in FVC or disease outcome.
 In our cohort, acute exacerbations of IPF (AE-IPF) oc-
curred in 11% of patients compared to 4.9% of patients 
treated with nintedanib in INPULSIS  [6] and were re-
sponsible for 42% of deaths during the follow-up period. 
As we know from the results of the INPULSIS trials,
AE-IPF tend to be more frequent in IPF patients with 
FVC  ≤ 70% pred. with a frequency ranging from 8 to 15% 
 [18] in treated and untreated patients, respectively. The 
incidence of AE-IPF in our cohort appears to be in line 
with these data.
 Nintedanib was well tolerated, with most side effects 
being mild to moderate in intensity. Similar to the results 
from clinical trials, the most frequent events were gastro-
intestinal, most commonly diarrhea (62%); this is also in 
agreement with results from postmarketing surveillance 
of the safety and tolerability of nintedanib in >3,500 pa-
tients treated in the United States  [19] . Diarrhea led to 
treatment discontinuation in 11% of patients treated in 
the CUP compared to 5% in the INPULSIS trials  [6] . The 
safety profile seen in the CUP is also consistent with a re-
cent communication on a cohort of 20 IPF patients treat-
ed with nintedanib from Spain  [20] , although 7 patients 
in this dataset had participated in the INPULSIS trials and 
therefore may have been affected by selection bias. We 
observed weight loss in 50% of patients (3 kg, on average, 
over 6 months). The number of patients with weight loss 
is much higher than observed with nintedanib treatments 
in the INPULSIS trials (8–11%), although it is similar to 
the Spanish experience in which 40% of patients (n = 
8/20) reported weight loss  [20] . Since we observed no sig-
nificant correlation between weight loss and patient char-
acteristics, previous treatment or response to nintedanib, 
the potential reasons for this difference are unknown. 
With regard to AEs of special interest, the tolerability pro-
file was similar to that previously reported in clinical trials 
 [5, 6] , and no new safety signals were detected in this
real-world setting; specifically liver enzyme elevations 
were manageable with dose reductions, and treatment in-
terruptions and monitoring intervals were adequate. It 
should be considered that patients entering the CUP were 
required to be ineligible for pirfenidone treatment based 
on disease severity and/or tolerability potentially result-
ing in a selection bias towards patients prone to tolerabil-
ity issues.
 There are several limitations to this study. Firstly, as 
the aim of the CUP was to provide nintedanib to those 
patients for whom no further approved treatment option 
was available, comprehensive and structured data collec-
tion was not achievable; hence, data were missing for a 
number of patients, and additional information that may 
have been of interest was not available. For example, just 
over three quarters of patients entering the CUP (n = 48) 
switched from pirfenidone. While patients were required 
to be ineligible for treatment with pirfenidone, based on 
disease severity and/or intolerability, the specific reasons 
for this switch were not documented; however, FVC data 
suggest that nearly half of these patients (n = 21) experi-
enced disease progression while on pirfenidone. Second-
ly, we did not use questionnaires to quantify symptoms 
or changes in quality of life, thus limiting the reliability of 
our results. In addition, data from 7 patients treated in 
one center, which have been reported previously  [21] , 
have not been excluded from the analysis.
 Conclusion 
 Our results from the real-life clinical setting support 
findings from previously conducted clinical trials and 
confirm that nintedanib is effective at slowing disease 
progression in patients with IPF and is well tolerated.
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